SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hansen Jesper)
 

Sökning: WFRF:(Hansen Jesper) > Treatment-free remi...

  • Flygt, HjalmarUppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden,Uppsala Univ Hosp, Sweden (författare)

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.

  • Artikel/kapitelEngelska2024

Förlag, utgivningsår, omfång ...

  • 2024
  • Springer,2024
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-524569
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-524569URI
  • https://doi.org/10.1038/s41375-024-02145-6DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-111229URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:155228509URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-202359URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial. Flygt, H., Söderlund, S., Richter, J. et al. Leukemia (2024). https://doi.org/10.1038/s41375-024-02184-z
  • Funding Agencies|Uppsala University
  • Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation. Most of them quickly regain DMR upon TKI resumption. Whether these patients can achieve a second treatment-free remission (TFR) remains unclear. DAstop2 (ClinicalTrials.gov ID: NCT03573596) is a prospective study including patients with a failed first TFR attempt re-treated with any TKI for ≥ one year. Upon entering the study, patients received the TKI dasatinib for additional two years. Patients with sustained DMR for ≥1 year qualified for a second TKI stop. Ninety-four patients were included between Oct 2017-Dec 2021. At the time of data analysis, 62 patients had attempted a 2nd stop. After a median follow-up of 27 months from 2nd stop, TFR rates were 61, 56 and 46% at 6, 12 and 24 months respectively. No progression to advanced stage disease was seen and 87% had re-achieved MR4 within a median of 3 months from TKI re-initiation. In summary, we show that a 2nd TFR attempt after dasatinib treatment is safe, feasible and TFR rates seem in the range of those reported in trials of a first TKI stop.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Söderlund, StinaUppsala universitet,Institutionen för medicinska vetenskaper,Department of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden,Uppsala Univ Hosp, Sweden (författare)
  • Richter, JohanDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden,Skane Univ Hosp, Sweden (författare)
  • Saussele, SusanneMedical Clinic, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany,Heidelberg Univ, Germany (författare)
  • Koskenvesa, PerttuDepartment of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland,Hematol Res Unit Helsinki, Finland; Helsinki Univ Hosp, Finland (författare)
  • Stenke, LeifKarolinska Institutet,Karolinska Univ Hosp, Sweden; Karolinska Inst, Sweden (författare)
  • Mustjoki, SatuDepartment of Hematology, Hematology Research Unit Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland; ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland,Hematol Res Unit Helsinki, Finland; Helsinki Univ Hosp, Finland; Univ Helsinki, Finland; Univ Helsinki, Finland; ICAN Digital Precis Canc Med Flagship, Finland (författare)
  • Dimitrijevic, AndrejaDepartment of Hematology, Odense University Hospital, Odense, Denmark,Odense Univ Hosp, Denmark (författare)
  • Stentoft, JesperDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark,Aarhus Univ Hosp, Denmark (författare)
  • Majeed, WaleedDepartment of Hemato-Oncology, Stavanger University Hospital, Stavanger, Norway,Stavanger Univ Hosp, Norway (författare)
  • Roy, LydiaFrench CML group Fi-LMC, Centre Léon Bérard, Lyon, Hôpital Universitaire Henri Mondor, AP-HP, Service d'hématologie Clinique & Faculté de Santé, Université Paris Est Créteil, Créteil, France,Univ Paris Est Creteil, France; Univ Paris Est Creteil, France (författare)
  • Wolf, DominikDepartment of Hematology and Oncology, Comprehensive Cancer Center Innsbruck (CCCI), Tyrolean Cancer Research Institute (TKFI), Medical University Innsbruck, Innsbruck, Austria; Medical Clinic 3, Universitätsklinikum, Bonn, Germany,Med Univ Innsbruck, Austria; Univ Klinikum Bonn, Germany (författare)
  • Dreimane, ArtaDepartment of Hematology, Linköping University Hospital, Linköping, Sweden,Region Östergötland, Hematologiska kliniken US(Swepub:liu)artdr13 (författare)
  • Gjertsen, Bjørn ToreDepartment of Internal Medicine, Hematology Section, Haukeland University Hospital, Bergen, Norway,Haukeland Hosp, Norway (författare)
  • Gedde-Dahl, TobiasDepartment of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway,Natl Hosp Norway, Norway (författare)
  • Ahlstrand, Erik,1974-Region Örebro län,Örebro universitet, Institutionen för medicinska vetenskaper,Department of Medicine,Orebro Univ, Sweden(Swepub:oru)ead (författare)
  • Markevärn, BeritDepartment of Hematology, Umeå University Hospital, Umeå, Sweden,Umea Univ Hosp, Sweden (författare)
  • Hjorth-Hansen, HenrikDepartment of Hematology, St. Olavs Hospital, Trondheim, Norway,St Olavs Hosp, Norway (författare)
  • Janssen, JeroenDepartment of Hematology, Radboud University medical center, Nijmegen, The Netherlands,Radboud Univ Nijmegen, Netherlands (författare)
  • Olsson-Strömberg, UllaDepartment of Medical Science and Division of Hematology, Uppsala University Hospital, Uppsala, Sweden,Uppsala Univ Hosp, Sweden (författare)
  • Uppsala universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Leukemia: Springer0887-69241476-5551

Internetlänk

Hitta via bibliotek

  • Leukemia (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy